Skip to main content
SpringerLink
Log in

Distribution study of radioactivity in rats after oral administration of the lipido/sterolic extract ofSerenoa repens (Permixon®) supplemented with [1-14C]-lauric acid, [1-14C]-oleic acid or [4-14C]-β-sitosterol

  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

The study carried out on rats given orally then-hexane lipido/sterolic extract ofSerenoa repens (LSESR), supplemented with [14C]-labelled oleic or lauric acids or β-sitosterol, demonstrated that radioactivity uptake in prostatic tissues shows the highest level in th case of administration of LSESR supplemented with [14C]-labelled oleic acid. This was clearly demonstrated on a rat with an induced fibro-muscular hyperplasia of the prostate and by quantitative measurements of radioactivity. Ratios of radioactivity in tissues compared to plasma show an uptake of radioactivity greater in prostate as compared to other genital organs, i.e. the seminal vesicles or to other organs such as liver.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Neuzil E., Cousse H. (1993): Le palmier-scieSerenoa repens: aspects botaniques et chimiques. Bull. Soc. Pharm. Bordeaux, 132, 121–141.

    CAS  Google Scholar 

  2. Small J.K. (1926): The saw-palmettoSerenoa repens, J. NY Bot. Gard., 27, 193–202.

    Google Scholar 

  3. Sherrard C.C. (1894): Saw palmetto (Sabal serrulata). Proc. Am. Pharm. Assoc., 42, 309–315.

    Google Scholar 

  4. Kraemer H. (1907): A text-book of botany and pharmacognosy, vol. 1, 2nd edn. Philadelphia: J.B. Lippincott.

    Google Scholar 

  5. Maisch V.M. (1899): A manual of organic materia, vol. 1, 7th edn. Philadelphia: Lea Brother.

    Google Scholar 

  6. Sayre L.E. (1907): A manual of organic materia and pharmacology, vol. A, 3rd edn. Philadelphia: P. Blakinston’s & Sons.

    Google Scholar 

  7. Shoemaker J.V. (1896): A practical treatise on materia medica and therapeutics with special reference to the clinical application of drugs. 2 vols, 4th edn. Philadelphia: Davis.

    Google Scholar 

  8. British Pharmaceutical Codex, vol. 1. (1923): 959.

  9. National Formulary. vol. 1, Am. Pharm. Assoc., 7th edn, pp 137; 8th edn, pp 457–459.

  10. Authie D., Cauquil J. (1987): Appréciation de l’efficacité de Permixon en pratique quotidienne. CR Thérap. Pharmacol. Clin., 5.

  11. Champault G., Patel J.C., Bonnard A.M. (1984): A double-blind trial of an extract of the plantSerenoa repens in benign prostatic hyperplasia, Br. J. Clin. Pharmacol., 18, 461–462.

    CAS  PubMed  Google Scholar 

  12. Cukier J., Ducassou A., Le Guillou F. et al. (1985): Permixon versus placebo. Résultats d’une étude multicentrique. C.R. Thérap. Pharmacol. Clin., 4, 16–21.

    Google Scholar 

  13. Descotes J.L., Rambeaud J.J., Deschaseaux P., Faure G. (1995): Placebo-controlled evaluation of the efficacy and tolerability of Permixon® in benign prostatic hyperplasia after exclusion of placebo responders. Clin. Drug Invest., 9, 291.

    Article  Google Scholar 

  14. Dathe G., Schmid H. (1991): Phytotherapie der benignen Protatahyperplasie (BPH) mit ExtractumSerenoa repens (Permixon). Urologe [B], 31, 220–223.

    Google Scholar 

  15. Sommer R.G. (1991): Sabalextract hat hohe therapeutische Qualität. Therapiewoche, 43, 114–115.

    Google Scholar 

  16. Boccafoschi C., Annoscia S. (1983): Confronto fra estratto diSerenoa repens e placebo mediante prova clinica controlate in pazienti con adenomatosi prostatica. Urologia, 30, 1257–1269.

    Google Scholar 

  17. Emili E., Lo Cigno M., Petrone U. (1983): Risultati clinici su un nuovo farmaco nelle terapia dell’ipertrofia della prostata (Permixon). Urologia, 30, 1032–1049.

    Google Scholar 

  18. Mandressi A., Tarallo U., Maggioni A., Tombolini P., Rocco F., Quadraccia P. (1987): Treatment of uncomplicated benign prostatic hypertrophy (BPH) by an extract of Serenoa repens. Clinical results. J. Endocrinol. Invest., 10 (Suppl. 2), 49–55.

    Google Scholar 

  19. Tasca A., Barulli M., Cavazzana A., Zattoni F., Artibani W., Pagano F. (1985): Trattamento della sintomatologia ostruttiva da adenoma prostatico con estratto diSerenoa repens. Minerva Urol. Nefrol., 37, 87–91.

    CAS  PubMed  Google Scholar 

  20. Olle Carreras J. (1987): Our experience with hexanic extract ofSerenoa repens in the treatment of benign prostatic hypertrophy. Arch. Espan. Urologia, 40, 310–313.

    CAS  Google Scholar 

  21. Neuzil E., Cousse H. (1993): Le palmier-scieSerenoa repens. Aspects pharmacologiques. Utilisation thérapeutique actuelle. Bull. Soc. Pharm. Bordeaux, 132, 142–163.

    CAS  Google Scholar 

  22. Breu W., Hagenlocher M., Redl K., Tittel G., Stadler F., Wagner H. (1992): Antiphlogistische Wirkung eines mit hyperkritischem Kohlendioxid gewonnenen Sabalfrucht-Extractes. In-vitro-Hemmung des Cyclooxygenase-und 5-Lipoxygenase Metabolismus. Arzneimittelforschung, 42, 547–551.

    CAS  PubMed  Google Scholar 

  23. Tarayre J.P., Delhon A., Lauressergues H. et al. (1983): Action anti-oedémateuse d’un extrait hexanique de drupes deSerenoa repens Bartr. Ann. Pharm. Fr., 41, 559–570.

    CAS  PubMed  Google Scholar 

  24. Carilla E., Briley M., Fauran F., Sultan C., Devillier C. (1984): Binding of Permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate. J. Steroid Chem., 20, 521–523.

    Article  CAS  Google Scholar 

  25. Vacher P., Prevarskaya N., Skryma R. et al. (1995): The lipidosterolic extract fromSerenoa repens interferes with prolactin receptor signal transduction. J. Biomed. Sci., 2, 357–365.

    Article  CAS  PubMed  Google Scholar 

  26. Delos S., Iehle C., Martin P.M., Raynaud J.P. (1994): Inhibition of the activity of basic 5α-reductase (type 1) detected in DU 145 cells and expressed in insect cells. J. Steroid Chem., 48, 347–352.

    CAS  Google Scholar 

  27. Wajda-Dubos J.P., Farines M., Soulier J., Cousse H. (1996): Etude comparative de la fraction lipidique des pulpes et graines deSerenoa repens. Oléagineux Corps gras Lipides, 3, 136–139.

    CAS  Google Scholar 

  28. Lee Robinette C. (1988): Sex-hormone-induced inflammation and fibromuscular proliferation in the rat lateral prostate. The Prostate, 12, 271–286.

    Article  Google Scholar 

  29. Ullberg S. (1954): Study on the distribution and fate of35S-labeled benzylpenicillin in the body. Acta Radiol., Suppl. 118, 1–110.

    CAS  Google Scholar 

  30. Benard P. (1991): Whole-body autoradiography of pharmaceuticals and chemicals. In: P.H. Bach & J.R.J. Baker, eds, Histochemical and immunohistochemical techniques: applications to pharmacology and toxicology. Chapman & Hall, London, pp 11–51.

    Google Scholar 

  31. Becker W., Bruce A. (1985): Autoradiographic studies with fatty acids and some other lipids: a review. Prog. Lipid Res., 24, 325–346.

    Article  CAS  PubMed  Google Scholar 

  32. Appelgren L.E. (1967): Sites of steroid hormone formation: autoradiographic studies using labelled precursors. Acta Physiol. Scand., Suppl. 301, 1–108.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pierre Fabre Médicament, Direction Générale, Castres, France

    H. Cousse

  2. Ecole Nationale Vétérinaire, Département des Sciences Biologiques et Fonctionnelles, Laboratoire de Radioéléments et d’Etudes Métaboliques, 23 chemin des Capelles, F-31076, Toulouse-Cedex, France

    G. Chevalier, P. Benard & T. Bengone

Authors
  1. G. Chevalier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Benard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Cousse
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. Bengone
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Footnote: Permixon® is marketed by Pierre Fabre Médicament (Castres, France) whose other trademarks include Capistan, Libeprosta and Sereprostat.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chevalier, G., Benard, P., Cousse, H. et al. Distribution study of radioactivity in rats after oral administration of the lipido/sterolic extract ofSerenoa repens (Permixon®) supplemented with [1-14C]-lauric acid, [1-14C]-oleic acid or [4-14C]-β-sitosterol. European Journal of Drug Metabolism and Pharmacokinetics 22, 73–83 (1997). https://doi.org/10.1007/BF03189787

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03189787

Keywords

Search

Navigation